Download PDF
Horm Metab Res 2003; 35(7): 402-406
DOI: 10.1055/s-2003-41620
Original Basic
© Georg Thieme Verlag Stuttgart · New York

Effects of Some Vanadyl Coordination Compounds on the In Vitro Insulin Release from Rat Pancreatic Islets

M.  T.  Conconi 1 , E.  De Carlo 2 , S.  Vigolo 1 , C.  Grandi 1 , G.  Bandoli 1 , N.  Sicolo 2 , G.  Tamagno 2 , P.  P.  Parnigotto 1 , G.  G.  Nussdorfer 3
  • 1Departments of Pharmaceutical Sciences, University of Padua, Padua, Italy
  • 2Departments of Medical and Surgical Sciences, University of Padua, Padua, Italy
  • 3Departments of Human Anatomy and Physiology, University of Padua, Padua, Italy
Further Information

Publication History

Received 24 October 2002

Accepted after Revision 8 January 2003

Publication Date:
21 August 2003 (online)

Also available at
    Permissions and Reprints

Abstract

Many lines of evidence indicate that vanadium inorganic salts possess insulin-mimetic and insulinotropic properties. However, they are poorly absorbed, so high oral doses are required to achieve effective plasma concentrations with possible undesirable toxic side-effects ensuing. Various organically-chelated vanadium compounds have been synthesized that are more potent than inorganic vanadium salts in their insulin-like effects due to their greater bioavailability. Unfortunately, little is known about the possible insulin secretagogue action of organic vanadyl coordination compounds. Hence, we investigated the effect of [VO(metformin)2]·H2O, [VO(salicylidene-ethylenedimmine)2] and [VO(pyrrolidine-N-dithiocarbamate)2](VODTC) on insulin release from isolated rat pancreatic islets, and compared it to that of vanadyl sulfate (VOSO4). Of the three coordination compounds, only VODTC was found to exert insulin secretagogue action. VODTC, within concentrations ranging from 0.1 to 1.0 mM, enhanced both basal and glucose (11 mM)-stimulated insulin release. The effect involves calcium channels, since it was not appreciable in Ca2+-free medium. The stimulating action of VODTC required the presence of the whole metal-chelator complex inasmuch as the chelator DTC alone was ineffective. VOSO4 was unable to bring about any significant rise in insulin release from isolated islets. Taken together, our findings indicate that VODTC may be considered a potential elective pharmaceutical tool in the therapy of diabetes, especially of type 2, through its concomitant stimulatory effect on insulin secretion and insulin-mimetic action.

Key words

Vanadium - Vanadyl coordination compounds - Pancreatic islets - Insulin - Rat

References

  • 1 Poucheret P, Verma S, Grynpas M D, McNeill J H. Vanadium and diabetes.  Mol Cell Biochem. 1998;  188 73-80
    CrossrefPubMedGoogle Scholar
  • 2 Gomez-Foix A M, Rodriguez-Gil J E, Fillat C, Guinovart J J, Bosh F. Vanadate raises fructose 2,6-bisphosphate concentrations and activates glycolysis in rat hepatocytes.  Biochem J. 1988;  255 507-512
    PubMedGoogle Scholar
  • 3 Blondel O, Bailte D, Portha B. In vivo insulin resistance in streptozotocin-diabetic rats. Evidence for reversal following oral vanadate treatment.  Diabetologia. 1989;  32 185-190
    CrossrefPubMedGoogle Scholar
  • 4 Brichard S M, Bailey C J, Henquin J C. Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats.  Endocrinology. 1989;  125 2510-2516
    PubMedGoogle Scholar
  • 5 Fantus I G, Ahmad F, Deragon G. Vanadate augments insulin binding and prolongs insulin action in rat adipocytes.  Endocrinology. 1990;  127 2716-2725
    PubMedGoogle Scholar
  • 6 Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kanh C R. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.  J Clin Invest. 1991;  87 1286-1294
    PubMedGoogle Scholar
  • 7 Shisheva A, Shechter Y. Role of cytosolic tyrosine kinase in mediating insulin-like actions of vanadate in rat adipocytes.  J Biol Chem. 1993;  268 6463-6469
    PubMedGoogle Scholar
  • 8 Carey J O, Azevedo J L, Morris P G, Pories W J, Dohm J L. Okadaic acid, vanadate, and phenylarsine oxide stimulate 2-deoxyglucose transport in insulin-resistant human skeletal muscle.  Diabetes. 1995;  44 682-688
    PubMedGoogle Scholar
  • 9 Castan I, Wijkander J, Manganiello V, Degerman E. Mechanisms of inhibition of lipolysis by insulin, vanadate and peroxovanadate in rat adipocytes.  Biochem J. 1999;  339 281-289
    CrossrefPubMedGoogle Scholar
  • 10 Matsuda M, Mandarino L, de Fronzo R A. Synergistic interaction of magnesium and vanadate on glucose metabolism in diabetic rats.  Metabolism. 1999;  48 725-731
    CrossrefPubMedGoogle Scholar
  • 11 Liu I M, Chi T C, Cheng J T. Decrease of hypothalamic neuropeptide Y gene expression by vanadyl sulphate in streptozotocin-induced diabetic rats.  Horm Metab Res. 2001;  33 96-100
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Boden G, Chen Z, Ruiz J, van Rossum G DV, Turco S. Effects of vanadyl sulphate on carbohydrate and lipid metabolism in patients with non insulin dependent diabetes mellitus.  Metabolism. 1996;  45 1130-1135
    CrossrefPubMedGoogle Scholar
  • 13 Goldfine A B, Simonson D C, Folli F, Patti M E, Kahn C R. Metabolic effects of sodium metavanadate in humans with insulin dependent and non insulin-dependent diabetes mellitus: in vivo and in vitro studies.  J Clin Endocrinol Metab. 1995;  80 3311-3320
    CrossrefPubMedGoogle Scholar
  • 14 Goldfine A B, Patti M E, Zuberi L, Goldstein B J, Le B lanc, Landaker E J, Jiang Z Y, Willsky G R, Kahn C R. Metabolic effects of vanadyl sulfate in humans with non insulin-dependent diabetes mellitus: in vivo and in vitro studies.  Metabolism. 2000;  49 400-410
    CrossrefPubMedGoogle Scholar
  • 15 Setyawati I A, Thompson K H, Yuen V G, Sun Y, Battel M, Lyster D M, Vo C, Ruth T J, Zeisler S, McNeill J H, Orvig C. Kinetic analysis and comparison of uptake, distribution and excretion of 48V-labeled compounds in rats.  J Appl Physiol. 1998;  84 569-575
    PubMedGoogle Scholar
  • 16 Mongold J J, Cros G H, Via L, Tep A, Ramanadham S, Siou G, Diaz J, McNeill J H, Serrano J J. Toxicological aspects of vanadyl sulphate on diabetic rats: effects on vanadium levels and pancreatic β-cell morphology.  Pharmacol Toxicol. 1990;  67 192-198
    PubMedGoogle Scholar
  • 17 Srivastava A K. Antidiabetic and toxic effects of vanadium compounds.  Mol Cell Biochem. 2000;  206 177-182
    CrossrefPubMedGoogle Scholar
  • 18 Woo L CY, Yuen V G, Thompson K H, McNeill J H, Orvig C. Vanadyl-biguanide complexes as potential synergistic insulin mimics.  J Inorg Biochem. 1999;  76 51-257
    PubMedGoogle Scholar
  • 19 Durai N, Saminathan G. Insulin-like effects of bis-salicylidine ethylenediimino oxovanadium(IV) complex on carbohydrate metabolism.  J Clin Biochem Nutrit. 1997;  22 1-39
    PubMedGoogle Scholar
  • 20 Reul B A, Amin S S, Buchet J P, Ongemba L N, Crans D C, Brichard S M. Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats.  Brit J Pharmacol. 1999;  126 467-477
    PubMedGoogle Scholar
  • 21 Kordowiak A M, Dabros W, Kajda B. The influence of a new vanadium compound, bis(2,2'-bipyridine)oxovanadium(IV) sulphate, on liver Golgi complexes from control and streptozotocin-diabetic rats.  Horm Metab Res. 2002;  34 556-560
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Sakurai H, Watanabe H, Tamura H, Yasui H, Matsushita R, Takada J. Insulin-mimetic vanadyl-dithiocarbamate complexes.  Inorg Chim Acta. 1998;  283 175-183
    CrossrefPubMedGoogle Scholar
  • 23 Orvig C, Thompson K H, Cam M C, McNeill J H. Vanadium compounds as possible insulin modifiers.  J Inorg Biochem. 1999;  76 93-105
    PubMedGoogle Scholar
  • 24 Bonadies J A, Carrano C J. Vanadium phenolates as model for vanadium in biological systems. Synthesis, spectroscopic and electrochemistry of vanadium complexes of ethylene-bis-[(o-hydroxyphenyl)glycine] and its derivatives.  J Am Chem Soc. 1986;  108 4088-4093
    CrossrefPubMedGoogle Scholar
  • 25 McCormick B J. The structure and spectra of dithiocarbamate complexes of oxovanadium(IV).  Inorg Chem. 1968;  7 1965-1970
    CrossrefPubMedGoogle Scholar
  • 26 Lacy P E, Kostianowsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas.  Diabetes. 1967;  16 35-39
    PubMedGoogle Scholar
  • 27 de Carlo E, Milanesi A, Martini C, Maffei P, Sicolo N, Scandellari C. Endothelin-1 and endothelin-3 stimulate insulin release by isolated rat pancreatic islets.  J Endocrinol Invest. 2000;  23 240-245
    PubMedGoogle Scholar
  • 28 Cadène A, Gross R, Poucheret P, Mongold J J, Masiello P, Roye M, Ribes G, Serrano J J, Cros G. Vanadyl sulphate differently influences insulin response to glucose in isolated pancreas of normal rats after in vivo or in vitro exposure.  Eur J Pharmacol. 1996;  318 145-151
    CrossrefPubMedGoogle Scholar
  • 29 Aspinwall C A, Lakey J RT, Kennedy R T. Insulin-stimulated insulin secretion in single pancreatic beta cells.  J Biol Chem. 1999;  274 6360-6365
    CrossrefPubMedGoogle Scholar
  • 30 Fagin J A, Ikejiri K, Levin S R. Insulinotropic effects of vanadate.  Diabetes. 1987;  36 1448-1452
    PubMedGoogle Scholar
  • 31 Voss C, Herrmann I, Hartmann K, Zühlke H. In vitro effect of vanadate on content, secretion and biosynthesis of insulin in isolated islets of normal Wistar rats.  Exp Clin Endocrinol. 1992;  99 159-163
    PubMedGoogle Scholar
  • 32 Zhang A, Gao Z Y, Gilon P, Nenquin M, Drews G, Henquin J C. Vanadate stimulation of insulin release in normal mouse islets.  J Biol Chem. 1991;  266 21 649-21 656
    PubMedGoogle Scholar
  • 33 Verma S, Cam M C, McNeill J H. Nutritional factors that can favourably influence the glucose/insulin system: vanadium.  J Am Coll Nutrit. 1998;  17 11-18
    PubMedGoogle Scholar
  • 34 Kahn B B. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance.  Cell. 1988;  92 593-596
    PubMedGoogle Scholar
  • 35 Ferrannini E. Insulin resistance versus insulin deficiency in non insulin-dependent diabetes mellitus: problems and prospects.  Endocr Rev. 1998;  19 477-490
    CrossrefPubMedGoogle Scholar
  • 36 McIntyre E A, Walker M. Genetics of type 2 diabetes and insulin resistance: knowledge from human studies.  Clin Endocrinol. 2002;  57 303-312
    CrossrefPubMedGoogle Scholar
  • 37 Cavaghan M K, Ehrmann D A, Polonski K S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance.  J Clin Invest. 2000;  106 329-333
    PubMedGoogle Scholar
  • 38 Marchetti P, Lupi R, Federici M, Marselli L, Masini M, Boggi U, Del G uerra, Patanè G, Piro S, Anello M, Bergamini E, Purrello F, Lauro R, Masca F, Sesti G, Del Prato S. Insulin secretory function is impaired in isolated human islets carrying the Gly972→Arg IRS-1 polymorphism.  Diabetes. 2002;  51 419-1424
    PubMedGoogle Scholar
  • 39 Rutter G A. Insulin secretion: feed-forward control of insulin biosynthesis?.  Current Biol. 1999;  17 R443-R445
    PubMedGoogle Scholar

Prof. G. G. Nussdorfer

Department of Human Anatomy and Physiology · Section of Anatomy

Via Gabelli 65 · 35121 Padova · Italy

Phone: + 39 (49) 827-2317

Fax: + 39 (49) 827-2319

Email: gastone.nusdorfer@unipd.it